JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2023, 72(2):79-94 | DOI: 10.5817/CSF2023-2-79

Marketing research of combined drugs for treatment of cardiovascular diseases

Nataliia S. Behei1,2,*, Oksana V. Tryhubchak1,2
1 Farmak JSC, Kyiv, Ukraine
2 Slovak Medical University in Bratislava, Slovak Republic

The work is devoted to the results of complex marketing research of all combined cardiovascular drugs. The market of combined drugs from group C according to the ATC classification in 41 countries of the world during 2019-2022 was analyzed. Segment markets of the 27 European Union countries, Albania, Belarus, Bosnia and Hercegovina, Canada, Colоmbia, Great Britain, India, Moldova, Norway, Russian Federation, Switzerland, and Ukraine, were studied. The pharmaceutical market of Australia and the United States were also studied. The structure of this group of drugs was characterized, and the most common combinations in the analyzed markets were identified. It was found that group C09 is the most filled with combined drugs, and the number of combinations is most diverse in C09 drug groups that act on the renin-angiotensin system, C10 hypolipidemic drugs, C07 beta-blockers, and C03 diuretics, which are the drugs of the first choice for arterial hypertension and coronary heart disease. There are two promising areas for expanding the range of drugs that affect the cardiovascular system.

Keywords: cardiovascular diseases; arterial hypertension; combined cardiovascular drugs; marketing research; directions of assortment expansion

Received: August 1, 2022; Accepted: January 10, 2023; Published: February 1, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Behei NS, Tryhubchak OV. Marketing research of combined drugs for treatment of cardiovascular diseases. Čes. slov. farm. 2023;72(2):79-94. doi: 10.5817/CSF2023-2-79.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Islam S. M. S., Purnat T. D., Phuong N. T. A., Mwingira U., Schacht K., Fröschl G. Non-Communicable Diseases (NCDs). In developing countries: a symposium report. Glob. Health 2014; 10(1), 1-8. Go to original source... Go to PubMed...
    2. van Camp G. Cardiovascular disease prevention. Acta Clinica Belgica: Cardiovascular disease prevention. Acta Clin. Belg: JCLA 2014; 69, 407-411. Go to original source... Go to PubMed...
    3. Kjeldsen S. E. Hypertension and cardiovascular risk: General aspects. Pharmacol. Res. 2018; 129, 95-99. Go to original source... Go to PubMed...
    4. Mancia G., de Backer G., Dominiczak A. ESH-ESC practice guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J. Hypertens. 2007; 25, 1751-1762. Go to original source... Go to PubMed...
    5. James P. A., Oparil S., Carter B. L., Cushman W. C., Dennison-Himmelfarb C., Handler J., Lackland D. T., LeFevre M., MacKenzie T. D.,Ogedegbe O., Smith S. C., Svetkey L. P., Taler S. J., Townsend R. R., Wright J. T., Narva A. S., Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults. JAMA 2014; 311(5), 507-520. Go to original source... Go to PubMed...
    6. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., Clement D. L., Coca A., Simone G., Dominiczak A., Kahan Th., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S. E., Kreutz r., Leurent S., Lip G. Y. H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R. E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J. 2018; 39(33), 3021-3104. Go to original source... Go to PubMed...
    7. Wright J. M., Musini V. M., Gill R. First-line drugs for hypertension. CDSR 2018; 4(4), CD001841. Go to original source... Go to PubMed...
    8. Hermida R. C., Ayala D. E., Fernández J. R., Portaluppi F., Fabbian F., Smolensky M. H. Circadian rhythms in blood pressure regulation and optimization of hypertension treatment with ACE inhibitor and ARB medications. AJH 2011; 24(4), 383-391. Go to original source... Go to PubMed...
    9. Austrian Federal Office for Safety in Health Care. Austrian Medicines and Medical Devices Agency: Austrian medicinal product index; 2020. Available from: https://aspregister.basg.gv.at/aspregister/faces/aspregister.jspx?_afrLoop=3064459845228608&_afrWindow-Mode=0&_adf.ctrl-state=15s1umdsu_4 (last accessed 25.04.2020).
    10. Agjencia Kombëtere e Bornave dhe Pajisjeve Mjekësore (AKBPM): Regjistri i barnave; 2020. Available from: http://www.akbpm.gov.al (last accessed 12.04.2020).
    11. Federal agency for medicines and health products: Medicinal Product Database. Medicinal Products; 2021. Available from: https://banquededonneesmedicaments.fagg-afmps.be/#/query/human/ (last accessed 17.01.2021).
    12. Ministry of health of the republic of Belarus. "Center for examinations and tests in health service". Republican unitary enterprise: Registers of the Unitary Enterprise "Center for Expertise and Testing in Healthcare"; 2021. Available from: https://www.rceth.by/Refbank/reestr_lekarstvennih_sredstvї (last accessed 03.08.2021).
    13. Bulgarian Drug Agency (BDA): Registration of medicinal products; 2019. Available from: https://ma.bda.bg/ial_register/Sites/PublicRegister/Default.aspx (last accessed 20.10.2019).
    14. Bosna i Hercegovina. Agencija za lijekove I medicinska sredstva: Spisak Lijekova; 2022. Available from: http://lijekovi.almbih.gov.ba:8090/SpisakLijekova.aspx (last accessed 12.02.2022).
    15. Danish Medicines Agency: Search results; 2022. Available from: https://laegemiddelstyrelsen.dk (last accessed 05.10.2022).
    16. Electronic medical compendium (emc): Search results; 2022. Available from: https://www.medicines.org.uk/emc/browse-medicines (last accessed 25.05.2022).
    17. EMC: Search results; 2022. Available from: https://www.medicines.org.uk (last accessed 05.10.2022).
    18. EOF: medicinal product search; 2022. Available from: http://www.eof.gr/web/guest/search (last accessed 25.05.2021).
    19. Finnish Medicines Agency Fimea: Search for a Medicine; 2022. Available from: https://www.fimea.fi (last accessed 05.10.2022).
    20. Le Figaro fr sante: Search for a Medicine; 2022. Available from: https://sante.lefigaro.fr (last accessed 05.10.2022).
    21. RX.ee. Еesti meditsiini portaal: ATC Kood; 2022. Available from: https://rx.ee/a (last accessed 25.05.2021).
    22. Health Products Regulatory Authority (HPRA): Search for a Medicine; 2022. Available from: http://www.hpra.ie/homepage/medicines/medicines-information/find-a-medicine/results?showadv=true&list=HM (last accessed 05.04.2021).
    23. Medline India: Pharmacological Index. Cardiovascular System; 2021. Available from: http://www.medlineindia.com/index.htm (last accessed 13.12.2021).
    24. Medicine Online Information Center of AEMPS - CIMA. Agencia Española de Medicamentos y Productos Sanitarios: Browser medicines; 2020. Available from: https://cima.aemps.es/cima/publico/buscadoravanzado.html (last accessed 10.03.2020).
    25. Torrinomedica: Farmaci. Codice ATC; 2021. Available from: https://www.torrinomedica.it (last accessed 12.12.2021).
    26. Gaverment of Canada: Drug Product Database; 2022. Available from: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp (last accessed 23.01.2021).
    27. GOV.CO. Portal Único del Estado Colombiano: Oficina Virtual Invima; 2021. Available from: https://www.invima.gov.co/component/content/article/213-tramites-y-servicios/consultas-registros-y-documentos-asociados/806-listado-codigo-unico-de-medicamentos.html (last accessed 10.10.2021).
    28. Republic of Cyprus - Pharmaceutical Services, Ministry of Health: Medicines search; 2022. Available from: https://www.phs.moh.gov.cy (last accessed 05.10.2022).
    29. State Agency of Medicines of the Republic of Latvia: Medicinal Product Register of Latvia; 2021. Available from: https://www.zva.gov.lv/zvais/zalu-registrs/?lang= -en (last accessed 20.10.2021).
    30. Ministry of Health of The Republic of Lithuania: Medicines search; 2021. Available from: https://vapris.vvkt.lt/vvkt-web/public/medications?lang=en (last accessed 15.10.2021).
    31. CNS. Le Gouvernement du Grand-Duché de Luxembourg: Liste des médicaments commercialisés.Triée par code ATC; 2021. Available from: https://cns.public.lu/fr/legislations/textes-coordonnes/liste-positive.html (last accessed 06.11.2021).
    32. Malta Medicine Authority: National Medecines; 2020. Available from: http://www.medicinesauthority.gov.mt/advanced-search (last accessed 10.09.2020).
    33. AMED: Clasificator medicamente; 2021. Available from: http://www.amed.md/ro/clasificator-medicamente (last accessed 14.07.2021).
    34. Medicines Evaluation Board: Medicines Information Bank; 2020. Available from: https://www.geneesmiddeleninformatiebank.nl/ords/f?p=111:1:0:::RP,1:P0_DOMAIN,P0_LANG:H,EN (last accessed 25.09.2020).
    35. BCFi: Repertoriun; 2020. Available from: http://www.bcfi.be/nl/start (Last accessed 02.11.2021).
    36. Rote Liste: Arzneimittelinformationen für Deutschland; 2021. Available from: https://www.rote-liste.de (last accessed 18.11.2021).
    37. States legemiddelverk: Legemiddelsøk; 2022. Available from: https://www.legemiddelsok.no/sider/default.aspx?searchquery=&f=Han;MtI;Vir;ATC;Var;for;Mar;-Mid;Avr;gen;par;&pane=0 (last accessed 10.03.2022).
    38. Informed: Medicines database; 2021. Available from: http://app7.infarmed.pt/infomed/pesquisa.php (last accessed 23.07.2021).
    39. Centrum e-Zdrowia: Rejestry mediczne; 2021. Available from: https://pub.rejestrymedyczne.csioz.gov.pl (last accessed 24.12.2021).
    40. State Register of Medicines: Pharmacotherapeutic group; 2022. Available from: https://grls.rosminzdrav.ru/grls.aspx (last accessed 09.03.2022).
    41. Agenția Națională a Medicamentului și a Dispozitivelor Medicale România (ANMDMR) - Nomenclatorul medicamentelor pentru uz uman: Lista medicamen-telor din NOMENCLATOR; 2021. Available from: https://www.anm.ro/nomenclator/medicamente (last accessed 10.11.2021).
    42. ADC: Humánne lieky; 2021. Available from: https://www.adc.sk/databazy/humanne-lieky?n=&nai=&cla=&frm=&hol=⊃=&code=&mf=&cat=&dr=∨d=a1 (last accessed 27.06.2021).
    43. Republika Slovenija Ministrstvo za zdravje: Centralna baza zdravil; 2021. Available from: http://www.cbz.si/cbz/bazazdr2.nsf/Search/$searchForm?SearchView (last accessed 25.05.2021).
    44. U.S. Food & Drug Administration: Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations; 2021. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm (last accessed 12.12.2021).
    45. Ministry of Health of Ukraine: State Register of Medicinal Products of Ukraine; 2022. Available from: http://www.drlz.com.ua (last accessed 25.03.2022).
    46. L'Agence nationale de sécurité du médicament (ANSM): Domaine medical. produit de santé; 2021. Available from: https://www.ansm.sante.fr/var/ansm_site/storage/original/application/07789b90857c5c64930a-53ec208907c9 (last accessed 20.09.2021).
    47. ALMP: Basa lijekova; 2021. Available from: http://www.almp.hr/en/Lijekovi/Baza-lijekova/#rezultati (last accessed 01.12.2021).
    48. Státní ústav pro kontrolu léčiv (SUKL): Databáze léků 2021. Available from: http://www.sukl.cz (last accessed 03.10.2021).
    49. Swiss Medic. Swiss Agency for Therapeutic Products: Lists and directories; 2021. Available from: https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html#-257211596 (last accessed 10.04.2021).
    50. Läkemedelsverket. Swedish Medical Products Agency: Drug; 2021. Available from: https://lakemedelsverket.se/LMF/?q=acetylsalicylsyra (last accessed 12.11.2021).
    51. National Institute of Pharmacy and Nutrition - institute of Hungary: Lists and directories 2022. Available from: https://ogyei.gov.hu (last accessed 05.10.2022).
    52. Wang J., Xiong X., Feng B. Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evid. Based Complement. Alternat. Med. 2013; 2013, ID 149363, 16. Go to original source... Go to PubMed...
    53. Domuschiev I. How the Natural Sedatives Hawthorn, Mint and Valerian Affect The Orthostatic Test by Measuring Pulse Rate Variability (PRV) in A 60-Year-Old Man. BJSTR 2021; 35(4), 27941-27942. Go to original source...
    54. Cheung M, Parmar M. Reserpine. In: StatPearls. Treasure Island (FL): StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK557767/(20.07.2022).
    55. Titko T., Perekhoda L., Drapak I., Tsapko Y. Modern trends in diuretics development. Eur. J. Med. Chem. 2020; 208, 112855. Go to original source... Go to PubMed...
    56. Mullens W., Damman K., Harjola V. P., Mebazaa A., Brunner-La Rocca H. P., Martens P., Testani J. M., Tang W. H. W., Orso F., Rossignol P., Metra M., Filippatos G., Seferovic P. M., Ruschchitzka F., Coats A. J. The use of diuretics in heart failure with congestion-a position statement from the Heart Failure Association of the European Society of Cardiology. EJHF 2019; 21(2), 137-155. Go to original source... Go to PubMed...
    57. Sarkar G., Gaikwad V. B., Sharma A., Halder S. K., Kumar D. A., Anand J., Mehta S. Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. Adv. Ther. 2022; 39(2), 923-942. Go to original source... Go to PubMed...
    58. Hocking K. M., Putumbaka G., Wise E. S., Cheung-Flynn J., Brophy C. M., Komalavilas P. Papaverine prevents vasospasm by regulation of myosin light chain phosphorylation and actin polymerization in human saphenous vein. PloS One 2016; 11(5), e0154460. doi:10.1371/journal.pone.0154460. Go to original source... Go to PubMed...
    59. Hnátek L. Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder. Vnitř. Lek. 2015; 61(9), 807-814.
    60. Gerges S. H., Wahdan S. A., Elsherbiny D. A., El-Demerdash E. Pharmacology of diosmin, a citrus flavone glycoside: an updated review. European Journal of Drug Metabolism and Pharmacokinetics 2021; 47(1), 1-18. Go to original source... Go to PubMed...
    61. Pareek A., Karnik N., Salagre S. B., Zawar S. D., Joglekar V. K., Chandurkar N., Naik G. S. Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicenter, randomized, controlled study. CMRO 2008; 24(6), 1771-1779. Go to original source... Go to PubMed...
    62. Gilarevskii S. R., Lantsova E. V., Akimov A. A. Efficacy and Safety of Combined Treament with Ivabradine and Metoprolol in Patients with Stable Angina Pectoris-a Systematic Review. Kardiologiia 2020; 60(11), 1357-1357. Go to original source... Go to PubMed...
    63. Leal U., Rincón D. Comparison of two products containing bisoprolol-hydrochlorothiazide therapeutic equivalence in patients with arterial hypertension. Revista Colombiana de Cardiología 2020; 27(4), 262-269. Go to original source...
    64. Regulski M., Regulska K., J Stanisz B., Murias M., Gieremek P., Wzgarda A., Niznik B. Chemistry and pharmacology of Angiotensin-converting enzyme inhibitors. Current Pharmaceutical Design 2015; 21(13), 1764-1775. Go to original source... Go to PubMed...
    65. Taddei S. Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence? Am. J. Cardiovasc. 2015; 15(3), 185-194. Go to original source... Go to PubMed...
    66. Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc. Health Risk Manag. 2009; 5(1): 411-427. doi: 10.2147/vhrm.s4235. PMID: 19475778; PMCID: PMC2686259. Go to original source... Go to PubMed...
    67. Borghi C., Soldati M., Bragagni A., Cicero A. F. Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients. Expert Opin. Drug Saf. 2020; 19(12), 1577-1583. Go to original source... Go to PubMed...
    68. Molvanov N. H., Tursunova D. E. Combined Antihypertensive and Hypolipidemic Therapy for Arterial Hypertension Hemodynamic Changes and Lipid Spectrum. IJHMS 2022; 1(1), 57-59.
    69. Pappa E., Rizos C. V., Filippatos T. D., Elisaf M. S. Emerging fixed-dose combination treatments for hyperlipidemia. JCPT 2019; 24(4), 315-322. Go to original source... Go to PubMed...
    70. Smith M. C. Principles of pharmaceutical marketing. New York: Routledge 2014. Go to original source...
    71. Kim D. W., Weon K. Y. Pharmaceutical application and development of fixed-dose combination: Dosage form review. J. Pharm. Investig. 2021; 51(5), 555-570. Go to original source...
    72. Ferrario A., Dedet G., Humbert T., Vogler S., Suleman F., Pedersen H. B. Strategies to achieve fairer prices for generic and biosimilar medicines. BMJ 2020; 368, 5444. Go to original source... Go to PubMed...
    73. Xanthopoulou S. S., Katsaliaki K. Policies and perceptions on generic drugs: The case of Greece. HSMR 2019; 32(1), 49-56. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.